Abiopharma

🔍 Morken David A. (Director)

Company: Bandwidth Inc. (BAND)

Report Date: 2026-08-28

Detailed Transactions and Holdings:

• Acquired 7,727 shares of Class A Common Stock (Direct)
  Date: 2026-08-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 7,727.00 | transaction_form_type: 4
• Acquired 4,103 shares of Class A Common Stock (Direct)
  Date: 2026-08-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,830.00 | transaction_form_type: 4
• Sold 3,000 shares of Class A Common Stock at $48.8226 per share (Direct)
  Date: 2026-08-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 8,830.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,128 shares of Class A Common Stock at $49.6021 per share (Direct)
  Date: 2026-08-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,702.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 7,727 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 7,727.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4
• Sold 4,103 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-28 | Code: M | equity_swap_involved: 0 | shares_owned_after: 20,514.00 | transaction_form_type: 4 | Footnotes: F3, F5, F5

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.29 to $49.28. The Reporting Person undertakes to provide Bandwidth Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.33 to $49.6351. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: Each Restricted Stock Unit represents a contingent right to receive one share of the Company's Class A Common Stock.
• F4: On November 28, 2023, the Reporting Person was granted 92,725 Restricted Stock Units, one third of which vested on the first anniversary of the date of grant and the remaining shares vest in eight equal quarterly installments beginning on February 28, 2025.
• F5: On November 28, 2024, the Reporting Person was granted 49,234 Restricted Stock Units, one third of which vested on the first anniversary of the date of grant and the remaining shares vest in eight equal quarterly installments beginning on February 28, 2026.